openPR Logo
Press release

Exosomes Pipeline Market Drug Profiles, Key Companies Insights and Key Products analysis report

10-15-2020 01:26 PM CET | Health & Medicine

Press release from: ReportsnReports

“Exosomes Market- Pipeline Insight, 2020” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Exosomes Pipeline Market landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
- Global coverage

Exosomes Understanding

Exosomes: Overview

Exosomes are small membrane vesicles of endocytic origin that are secreted by most cells in culture and are created upon the fusion of the multivesicular body (MVB)-an intermediate endocytic compartment-with the plasma membrane. They are nano-sized vesicles capable of transferring DNAs, micro RNAs, non-coding RNAs, and lipids, with or without direct cell-to-cell contact, which represents a novel method of intracellular communication. MVB’a type of intraluminal vesicles (ILV’s)-buds inward into the endosomal lumen. Exosomes, produced in endosomal compartment of most eukaryotic cells, are released in the form of ILV’s in instances where the MVB fuses with the cell surface (the plasma membrane). The exosomes and other extracellular vesicles (EV’s) are present in tissues of the multicellular organisms, including biological fluids, such as blood, urine, and cerebrospinal fluid. They can also be released in vitro by the cultured cells into their growth medium.

Get Free Sample Copy of Exosomes Market Pipeline Research Report at https://www.reportsnreports.com/contacts/requestsample.aspx?name=3715977

Characteristics of Exosomes and Function

Exosomes are basically formed by the cellular endocytic pathway, which consists of three different stages:
- The plasma membrane invagination from the endocytic vesicles.
- The second stage is the inward building of endosomal membrane which gives rise to multivesicular bodies (MVB’s).
- The third and the last stage is when the MVB’s fuse with the plasma membrane and releases the vesicular contents, which in turn forms the exosomes.

The membrane proteins, which undergo the endosomal pathway, exhibit the same stages. Different types of lipidic molecules are known for their involvement in the exosome formation and release like phosphatidic acid and ceramides.

Composition

Due to its protein and lipid content, exosomes are special, providing an additional hint for their identification. Exosomes mainly include fusion and transport proteins (annexins and flotillin), heat shock proteins (HSP70), CDís proteins (CD9, CD81), and phospholipases and other lipid-related proteins. Due to its protein and lipid content, exosomes are special, providing an additional hint for their identification. Exosomes mainly include fusion and transport proteins (annexins and flotillin), heat shock proteins (HSP70), CDís proteins (CD9, CD81), and phospholipases and other lipid-related proteins. One can use all of these proteins as positive markers.

Biological functions of Exosomes

Exosomes are nano-sized EVs that have impressive physiological properties and emerge through the inward budding of the late endosomal membrane called multivesicular bodies (MVBs). As MVBs are fused with the plasma membrane, exosomes are released into the extracellular environment. They can either be taken up by target cells residing in the microenvironment or transported by biological fluids to distant sites. Exosomes have a small diameter range of 40–100 nm and a density of 1.13-1.19 g/ml in sucrose solution. They can be sedimented at 100,000 g by centrifugation. Also, exosome membranes are enriched with proteins from cholesterol, sphingomyelin, ceramide and lipid raft.

Get 20% Discount on this Research Report at https://www.reportsnreports.com/contacts/discount.aspx?name=3715977

Exosomes Emerging Drugs Chapters

This segment of the Exosomes report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Exosomes Emerging Drugs
- Neural exosomes (AB126): ArunA Biomedical

ArunA Biomedical’s proprietary neural exosomes cross the blood-brain barrier inherently and enable drugs and drug-combinations to naturally target cells and treat patients with a range of neurological disorders. Preclinical studies have demonstrated the therapeutic potential of these exosomes in multiple stroke models. These studies have shown that the exosomes enhance the nervous system’s self-repair mechanisms, translating into structural and functional benefits which may have improved survival, reduced infarct size, and improved mobility.
- ExoPr0: ReNeuron

Company’s CTX-derived exosomes candidate is currently in the preclinical stage and is being developed as a novel vector for delivering the third party biological drugs. ExoPr0 has demonstrated potential as both a novel therapeutic candidate as well as a drug delivery vehicle in established preclinical disease models. The company intends to devote more significant resource to the application of ExoPr0 as a vector for delivering drugs.
- exoIL-12: Codiak Biosciences

exoIL-12 is a precision-engineered exosome therapeutic candidate expressing IL-12 on the surface of the exosome by molecular fusion to Codiak’s proprietary scaffold protein, PTGRFN. Developed via Codiak’s proprietary engEx platform, exoIL-12 is designed to target T-cells and Natural Killer cells and induce systemic anti-tumor immunity. Data from Codiak’s preclinical studies suggest that when administered intratumorally, exoIL-12 is retained in the tumor microenvironment, thus resulting in potent antitumor immunity and an improved toxicity profile compared to recombinant IL-12.

Direct Purchase of this Research Report at https://www.reportsnreports.com/purchase.aspx?name=3715977

Further product details are provided in the report..

Exosomes: Therapeutic Assessment

This segment of the report provides insights about the different Exosomes based drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Exosomes

There are approx. 50+ key companies which are developing the therapies for Exosomes. The companies which have their Exosomes drug candidates in the early stages, i.e. phase I include United Therapeutics Corporation.
- Phases

DelveInsight’s report covers around 50+ products under different phases of clinical development like
- Late-stage products (Phase II and Phase II/III)
- Mid-stage products (Phase II and Phase II/III)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates

- Route of Administration

Exosomes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Intramuscular
- Intranasal
- Parenteral
- Intravenous
- Topical
- Molecule Type

Products have been categorized under various Molecule types such as
- Small molecules
- Vaccines
- Polymers
- Peptides
- Enzymes

- Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Exosomes Market: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Exosomes therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Exosomes drugs.

Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Exosomes R&D. The therapies under development are focused on novel approaches to treat/improve Exosomes.
- Anjarium’s Hybridosome platform, coupled with the targeting technology and proprietary manufacturing methods, is a promising technology to overcome the delivery hurdles today’s most potent RNA therapeutic candidates face.
- Therapeutic Benefits: Exosomes are directly internalized by recipient cells, which prevent a multiplicity of potential concerns associated with the administration of living cells, and exosomes have therapeutic benefits, at least equivalent to their cellular source.

For More details with TOC and List of figures and table, Browse complete Report at https://www.reportsnreports.com/reports/3715977-exosomes-pipeline-insight-2020.html

Exosomes Report Insights
- Exosomes Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs

Exosomes Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Exosomes drugs?
- How many Exosomes drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Exosomes?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Exosomes therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Exosomes and their status?
- What are the key designations that have been granted to the emerging drugs?

Key Players
- Direct Biologics
- Codiak BioSciences
- ExoCyte Therapeutics
- Avalon GloboCare
- United Therapeutics Corporation
- Capricor Therapeutics
- Avalon GloboCare
- Azymus Therapeutics
- Versatope Therapeutics
- Lamellar Biomedical
- Celltrion

Key Products
- LAMELLASOME IPF-NA
- exoSTING
- ET-08
- AVA 201
- Unexisome
- CAP 2003
- exoIL 12
- AVA 203
- AZ 001
- VT 105

ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.

+ 1 888 391 5441
sales@reportsandreports.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Exosomes Pipeline Market Drug Profiles, Key Companies Insights and Key Products analysis report here

News-ID: 2160690 • Views:

More Releases from ReportsnReports

DeviceCon Series 2024 - UK Edition | MarketsandMarkets
DeviceCon Series 2024 - UK Edition | MarketsandMarkets
Future Forward: Redefining Healthcare with Cutting-Edge Devices Welcome to DeviceCon Series 2024 - Where Innovation Meets Impact! Join us on March 21-22 at Millennium Gloucester Hotel, 4-18 Harrington Gardens, London SW7 4LH for a groundbreaking convergence of knowledge, ideas, and technology. MarketsandMarkets proudly presents the DeviceCon Series, an extraordinary blend of four conferences that promise to redefine the landscape of innovation in medical and diagnostic devices. Register Now @ https://events.marketsandmarkets.com/devicecon-series-uk-edition-2024/register MarketsandMarkets presents
5th Annual MarketsandMarkets Infectious Disease and Molecular Diagnostics Conference Promises New Trends and Insights in Diagnosis
5th Annual MarketsandMarkets Infectious Disease and Molecular Diagnostics Confer …
London, March 7, 2024 - MarketsandMarkets is thrilled to announce the eagerly awaited 5th Annual Infectious Disease and Molecular Diagnostics Conference, scheduled to take place on March 21st - 22nd, 2024, at the prestigious Millennium Gloucester Hotel, located at 4-18 Harrington Gardens, London SW7 4LH. This conference promises to be a groundbreaking event, showcasing the latest trends and insights in diagnosis, as well as unveiling cutting-edge technologies that are revolutionizing the
Infection Control, Sterilization & Decontamination Conference |21st - 22nd March 2024| Challenges and Factors affecting in Sterilization of medical devices and more
Infection Control, Sterilization & Decontamination Conference |21st - 22nd March …
MarketsandMarkets is pleased to announce its 8th Annual Infection Control, Sterilisation, and Decontamination in Healthcare Conference, which will take place March 21-22, 2024, in London, UK. With the increased risk of infection due to improper sterilisation and decontamination practices, the safety of patients and healthcare workers is of paramount importance nowadays. Enquire Now @ https://events.marketsandmarkets.com/infection-control-sterilization-and-decontamination-conference/ This conference aims to bring together all the stakeholders to discuss the obstacles in achieving
Breast Augmentation Market Key Players, Demands, Cost, Size, Procedure, Shape, Surface and Forecast to 2025
Breast Augmentation Market Key Players, Demands, Cost, Size, Procedure, Shape, S …
The global Breast Augmentation Market in terms of revenue was estimated to be worth $900 million in 2020 and is poised to reach $1,692 million by 2025, growing at a CAGR of 13.4% from 2020 to 2025. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying

All 5 Releases


More Releases for Exosomes

Exosomes Market to Witness Comprehensive Growth by 2030
Acumen Research and Consulting has announced the addition of the "Exosomes Market" report to their offering. The Exosomes Market Report 2030 is an in depth study analyzing the current state of the Exosomes Market. It provides brief overview of the market focusing on definitions, market segmentation, end-use applications and industry chain analysis. The study on Exosomes Market provides analysis of China market covering the industry trends, recent developments in the market
Global Exosomes Market Size - Forecast to 2026
As per the research conducted by GME, the Exosomes Market is estimated to be valued at USD 1.82 Billion in 2021 and is projected to reach USD 5.58 Billion by 2026 at a CAGR of 25.12%. The expanding preponderance of cancer, technological breakthroughs in exosome isolation & analytical procedures, and enhancing the innovative capabilities of exosomes are among the considerations supporting global exosomes market advancement. Browse 151 Market Data Tables
Exosomes News: Creative Biolabs Introduces Exosome Purification Services for Car …
As exosomes can transmit the information of donor cells to recipient cells through the proteins, mRNA, miRNA carried by them, thus to realize the information and material exchange between cells, they have been a hot topic recently as being used as a drug carrier to transport drugs. "Future research may focus on how to improve the cargo loading of exosomes," said the senior scientist from Creative Biolabs, “at present, some
Exosomes Market Growth Trends, Factors and Comprehensive Analysis by 2027
Exosomes market is expected to grow during the forecast period owing to the key driving factors such as rising healthcare expenditure, increase prevalence of cancer, raising emphasis on early diagnosis of cancer, increase oncology research, awareness related to healthcare and others. In addition, various players in the emerging market have strong pipeline product and high potential which are anticipated to create several growth opportunities for the market during the forecast
Exosomes Market by Growth Analysis 2019 | Fujifilm, Thermo Fisher Scientific, Da …
The Global Exosomes market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Exosomes Market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global Exosomes market.
Exosomes Market 2018 Trend, Segmentation and Opportunities Forecast To 2025
This report studies the global Exosomes market size, industry status and forecast, competition landscape and growth opportunity. This research report categorizes the global Exosomes market by companies, region, type and end-use industry. Get Free Sample Copy of Report at https://www.researchformarkets.com/sample/global-exosomes-market-107652 This report focuses on the global top players, covered Fujifilm, Danaher, Lonza, Illumina, Inc., Thermo Fisher Scientific, Qiagen, Takara Bio Company, Malvern Instruments, Hitachi Chemical Diagnostics, Miltenyi Biotec, Diagenode, Novus Biologicals, New